135 related articles for article (PubMed ID: 17484896)
21. ATP-binding domain of NTPase/helicase as a target for hepatitis C antiviral therapy.
Borowski P; Mueller O; Niebuhr A; Kalitzky M; Hwang LH; Schmitz H; Siwecka MA; Kulikowsk T
Acta Biochim Pol; 2000; 47(1):173-80. PubMed ID: 10961691
[TBL] [Abstract][Full Text] [Related]
22. Tailoring antiviral therapy in hepatitis C.
Davis GL
Hepatology; 2006 May; 43(5):909-11. PubMed ID: 16628667
[No Abstract] [Full Text] [Related]
23. Prediction of relapse following treatment for hepatitis C: is whole blood more than the sum of its parts?
Shire N; Koziel MJ
Clin Infect Dis; 2004 Dec; 39(12):1761-3. PubMed ID: 15578396
[No Abstract] [Full Text] [Related]
24. Physician do no harm.
Cameron S
Antivir Ther; 2012; 17(6):1101. PubMed ID: 22647550
[No Abstract] [Full Text] [Related]
25. The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus.
Dixit NM; Perelson AS
Cell Mol Life Sci; 2006 Apr; 63(7-8):832-42. PubMed ID: 16501888
[TBL] [Abstract][Full Text] [Related]
26. Highly active macromolecular prodrugs inhibit expression of the hepatitis C virus genome in the host cells.
Ruiz-Sanchis P; Wohl BM; Smith AA; Zuwala K; Melchjorsen J; Tolstrup M; Zelikin AN
Adv Healthc Mater; 2015 Jan; 4(1):65-8. PubMed ID: 25132665
[TBL] [Abstract][Full Text] [Related]
27. Ribavirin analogs.
Shields WW; Pockros PJ
Clin Liver Dis; 2009 Aug; 13(3):419-27. PubMed ID: 19628158
[TBL] [Abstract][Full Text] [Related]
28. Viral kinetics in hepatitis C.
Lutchman G; Hoofnagle JH
Hepatology; 2003 Jun; 37(6):1257-9. PubMed ID: 12774002
[No Abstract] [Full Text] [Related]
29. Modeling the antiviral activity of ribavirin against hepatitis C virus in cell culture.
Felmlee DJ; Xiao F; Baumert TF
Hepatology; 2013 Oct; 58(4):1203-6. PubMed ID: 23703706
[No Abstract] [Full Text] [Related]
30. Viral load monitoring: shifting paradigms in clinical practice.
Baum P; Heilek G
MLO Med Lab Obs; 2013 Nov; 45(11):8, 10, 12 passim. PubMed ID: 24313118
[No Abstract] [Full Text] [Related]
31. Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications.
Vignuzzi M; Stone JK; Andino R
Virus Res; 2005 Feb; 107(2):173-81. PubMed ID: 15649563
[TBL] [Abstract][Full Text] [Related]
32. Lethal mutagens: broad-spectrum antivirals with limited potential for development of resistance?
Freistadt MS; Meades GD; Cameron CE
Drug Resist Updat; 2004 Feb; 7(1):19-24. PubMed ID: 15072768
[TBL] [Abstract][Full Text] [Related]
33. Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis.
Ortega-Prieto AM; Sheldon J; Grande-Pérez A; Tejero H; Gregori J; Quer J; Esteban JI; Domingo E; Perales C
PLoS One; 2013; 8(8):e71039. PubMed ID: 23976977
[TBL] [Abstract][Full Text] [Related]
34. The role of ribavirin-induced mutagenesis in HCV therapy: a concept or a fact?
Hong Z
Hepatology; 2003 Oct; 38(4):807-10. PubMed ID: 14512867
[No Abstract] [Full Text] [Related]
35. Ribavirin-free treatment may soon be a reality.
Al-Judaibi B
Saudi J Gastroenterol; 2015; 21(4):260-1. PubMed ID: 26228372
[No Abstract] [Full Text] [Related]
36. Novel therapies for hepatitis C virus based on lessons from virology.
Glenn JS
Clin Gastroenterol Hepatol; 2005 Oct; 3(10 Suppl 2):S86-8. PubMed ID: 16234068
[TBL] [Abstract][Full Text] [Related]
37. The mechanism of action of ribavirin: lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependent RNA polymerase.
Cameron CE; Castro C
Curr Opin Infect Dis; 2001 Dec; 14(6):757-64. PubMed ID: 11964896
[TBL] [Abstract][Full Text] [Related]
38. Resistance of high fitness hepatitis C virus to lethal mutagenesis.
Gallego I; Gregori J; Soria ME; García-Crespo C; García-Álvarez M; Gómez-González A; Valiergue R; Gómez J; Esteban JI; Quer J; Domingo E; Perales C
Virology; 2018 Oct; 523():100-109. PubMed ID: 30107298
[TBL] [Abstract][Full Text] [Related]
39. Counteracting quasispecies adaptability: extinction of a ribavirin-resistant virus mutant by an alternative mutagenic treatment.
Perales C; Agudo R; Domingo E
PLoS One; 2009; 4(5):e5554. PubMed ID: 19436746
[TBL] [Abstract][Full Text] [Related]
40. SASLT position statement on the direct-acting antiviral agents for the treatment of hepatitis C virus infection.
Alghamdi AS; Alqutub A; Abaalkhail F; Sanai FM; Alghamdi H; Altraif I; Alswat KA; Alghamdi MY; Babatin MA; Alfaleh FZ
Saudi J Gastroenterol; 2015; 21(2):60-3. PubMed ID: 25843190
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
